Left ventricular assist devices (LVADs) are increasingly used in the treatment of patients with severe left heart failure. However, as reported by large registries and observational studies, after an initial improvement in the first months after implantation, functional capacity and, in parallel, quality of life do not improve further subsequently. 1 Besides the potential confounding effect of comorbidities and of frailty, driveline or pump infections and surgical complications, this phenomenon can be partly attributed to the consequences of the unique pathophysiology of a pump providing continuous flow on haemodynamics, coagulation and organ function. Continuous flow pumps have indeed substituted for several years pulsatile flow pumps, due to demonstrated better survival rates in a randomized trial. 2 On the other hand, it must be considered that a consistent number of LVAD patients have a haemodynamic profile that is not sufficiently optimized by pump settings, 3 revealing an insufficient unloading by the LVAD and the need for adjusting pump speed or medications.
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Thus, any attempt to improve the functional capacity and quality of life of these patients with the devices actually available on the market must be made through an assessment of the degree of support given by the pump, and an optimization of pump settings and medications.
The current review by Laoutaris 4 mainly focuses on the role of modifying pump speed to favour pulsatility on functional capacity and complications and it analyses well the limits of our actual knowledge about it, providing an extensive review. In the present paper, as in most published studies, pulsatility is presented as a concept rather than as a precisely calculated value; indeed, its calculation can be difficult and it is variously defined: it generally refers to the pulse pressure (the difference between the systolic and diastolic pressure) or to the pulsatility index, that is, the ratio between the peak and minimum excursion in flow velocity and the mean velocity. A low pulsatility has been advocated to be associated with increased rates of aortic insufficiency and bleeding; 5 HVAD and Heartmate 3 (HM-3) provide the possibility of estimate pulsatility and pulsatility index respectively and have incorporated features favouring pulsatility and aortic valve opening (Lavare cycle for HVAD and artificial pulse for HM-3), but, even if the rate of complications has decreased compared with the previous devices, thrombosis and bleeding still remain frequent in this population of patients, thus meaning that our understanding of pulsatility and its control is still not complete.
Adjusting the pump speed is another way of varying pulsatility, and the author focuses broadly on this aspect, reporting that studies investigating this approach have shown only small improvements in functional capacity increasing pump speeds, and a possible increase in aortic regurgitation, and a higher probability of suction events and arrhythmias. On the other hand, a lower pump speed could lead to a lower degradation of von Willebrand factor (vWF), that is one important source of bleeding in LVAD patients, but, as Laoutaris reports, some papers showed that a lower speed can lead to lower functional capacity without affecting clearly the degradation rates of vWF; moreover, lower pump speed can worsen the haemodynamic profile, with higher filling pressures, as reported by haemodynamic ramp tests. Therefore, the advantage of an approach focused on favouring physiological pulsatility is still under debate, with some authors supporting this hypothesis and others underlining the limits of this approach.
Another important aspect to be considered is that, in a physiological system, heart function and the pressure gradients between left ventricle and aorta during cardiac cycle are main determinants of pulsatility, but blood flow to the peripheral organs depends also on the elastic properties of blood vessels and their ability to transform the kinetic energy provided by the ejection of the blood from the heart in elastic energy during diastole (Windkessel's effect); this latter aspect may be related to endothelial function and physical activity. 6 The calculation of energy-equivalent pressure (rather than pressure gradients) would therefore probably be a more precise parameter to estimate the driving force of blood flow, but its application in clinical practice is difficult and its role in the setting of LVAD is poorly explored. The lack of knowledge about the role of the energy forces involved in flow to the organs and to the periphery in LVAD patients and the elastic properties of the vessels is an interesting field of research that could help to achieve a better understanding of LVAD physiology in the context of continuous pump support. In this field arises an important aspect of the present review: the role of physical exercise. The Author reports studies showing that exercise training can lower peripheral vascular resistances and improving the contribution of the heart to overall cardiac output. Thus, the hypothesis of the present review is that exercise training could lead to a higher contribution of the heart to blood flow, an improvement in endothelial function and therefore a higher degree of pulsatility. This hypothesis is innovative, but it has also some limitations: first of all, consideration must be given to the possible role of right ventricular function, to the functional capacity and to the response of pump flow to exercise; second, current available pumps do not have an algorithm that allows to change the speed during exercise and therefore the provided flow could be insufficient; 7 third, as the Author points out, the role of frailty and comorbidities on exercise capacity must be taken into account. Even if LVAD therapy can improve muscular function, there is the need to promote cardiac rehabilitation in this setting of patients, especially in the post operative phase, to improve frailty. 8 Another aspect not analysed in the present paper is the role of exertional oscillatory ventilation, a condition characterized by periods of hyperpnoea and hypopnoea without interposed apnoea during exercise; the prevalence of this well known prognostic marker after LVAD implantation remains similar to the one observed in patients with severe heart failure. 9 Finally, in the setting of LVAD, it must kept in mind that pump flow is dependent on preload (thus on volume status and right ventricular function), afterload (aortic pressure and peripheral vascular resistances) and pump speed. Therefore, even if the residual left ventricular function generates pulsatility and pressure, LVAD flow and overall pulsatility can be strongly influenced by fluid balance, arterial pressure and right ventricular function, which can be influenced by medications.
The present review analyses the role of beta blockers, but in the literature there is an incredible paucity of data about the role of medical therapy in LVAD patients: even if the percentages of use of heart failure drugs are reported by the INTERMACS Registry, 10 we still do not know whether common drugs for heart failure can improve prognosis in these patients and how they interact with the pump settings. This latter aspect reflects a gap between our knowledge of technology and the comprehension of pathophysiology and management in LVAD patients; a proof of that is the finding of a consistent number of cases in whom the haemodynamic profile is not adequately optimized by LVAD; this can be due to inadequate pump speed, low levels of use of heart failure drugs due to a low level of evidence about them or, in some cases, to a low attitude to performing invasive haemodynamics tests due to a low expertise of the implanting centre.
In conclusion, the present review, summarizing the available evidence on regulation of pump speed and pulsatility on exercise capacitance, suggests exercise training as a possible way to favour pulsatility, thus indicating a potential new field of research, but it highlights the still big lack of knowledge in this fascinating field of medicine to improve quality of life of these patients.
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